Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Database study of carfilzomib treatment after daratumumab in multiple myeloma
jRCT1050250062Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2025
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Ono Pharmaceutical. Primary endpoints: Treatment patterns after daratumumab, Efficacy of carfilzomib after daratumumab exposure (primary) and 1 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT1050250062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050250062.